Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Short-term Investments (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Short-term Investments for 11 consecutive years, with $131.1 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 32.85% to $131.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.1 million through Dec 2025, down 32.85% year-over-year, with the annual reading at $131.1 million for FY2025, 32.85% down from the prior year.
  • Short-term Investments hit $131.1 million in Q4 2025 for Voyager Therapeutics, down from $163.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $294.9 million in Q2 2024 to a low of $5.0 million in Q1 2023.
  • Historically, Short-term Investments has averaged $112.2 million across 5 years, with a median of $100.4 million in 2022.
  • Biggest five-year swings in Short-term Investments: tumbled 85.72% in 2023 and later surged 5036.99% in 2024.
  • Year by year, Short-term Investments stood at $15.1 million in 2021, then surged by 31.66% to $19.9 million in 2022, then surged by 714.89% to $162.1 million in 2023, then grew by 20.51% to $195.3 million in 2024, then tumbled by 32.85% to $131.1 million in 2025.
  • Business Quant data shows Short-term Investments for VYGR at $131.1 million in Q4 2025, $163.8 million in Q3 2025, and $171.7 million in Q2 2025.